May 2 2014

Americord Funds Clinical Trial Investigating Stem Cell Therapy for Alzheimer’s Disease

Posted by admin

Funds Will Support Research Into Safety and Efficacy of NEUROSTEM-AD®

New York – May 2, 2014 – Americord announced today that it has provided funding to MEDIPOST, a leading stem cell biotechnology company, to support their clinical trial investigating the use of NEUROSTEM-AD® in the treatment of patients with Alzheimer’s Disease. NEUROSTEM-AD® is a treatment agent for Alzheimer’s Disease that uses human umbilical cord blood-derived mesenchymal stem cells.

This is the first donation that Americord has made under its recently launched corporate giving program, which was established to support research focused on the therapeutic uses of stem cells from umbilical cord blood, cord tissue, and placenta tissue.

“At Americord, we are committed to assisting the world’s leading scientists as they pursue cutting edge stem cell-based therapies for diseases and conditions that have long-proved to be difficult or impossible to treat,” said Americord CEO Martin Smithmyer. “We are thrilled to make a donation to MEDIPOST to support their research into the treatment of Alzheimer’s Disease with a stem cell-based therapy.”

MEDIPOST’s study began in February 2014 and is anticipated to be complete by December 2015. It is registered with in accordance with best practices and requirements of the U.S. Food and Drug Administration.

< Back to Blog
Category: Press